IBDEI0PQ ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,11565,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11565,1,3,0)
;;=3^Secondary Hyperparathyroidism of Renal Origin
;;^UTILITY(U,$J,358.3,11565,1,4,0)
;;=4^N25.81
;;^UTILITY(U,$J,358.3,11565,2)
;;=^5015617
;;^UTILITY(U,$J,358.3,11566,0)
;;=E22.2^^46^559^28
;;^UTILITY(U,$J,358.3,11566,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11566,1,3,0)
;;=3^SIADH
;;^UTILITY(U,$J,358.3,11566,1,4,0)
;;=4^E22.2
;;^UTILITY(U,$J,358.3,11566,2)
;;=^5002718
;;^UTILITY(U,$J,358.3,11567,0)
;;=E87.79^^46^559^10
;;^UTILITY(U,$J,358.3,11567,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11567,1,3,0)
;;=3^Fluid Overload,Other
;;^UTILITY(U,$J,358.3,11567,1,4,0)
;;=4^E87.79
;;^UTILITY(U,$J,358.3,11567,2)
;;=^5003025
;;^UTILITY(U,$J,358.3,11568,0)
;;=E21.0^^46^559^27
;;^UTILITY(U,$J,358.3,11568,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11568,1,3,0)
;;=3^Primary Hyperparathyroidism
;;^UTILITY(U,$J,358.3,11568,1,4,0)
;;=4^E21.0
;;^UTILITY(U,$J,358.3,11568,2)
;;=^331439
;;^UTILITY(U,$J,358.3,11569,0)
;;=E87.71^^46^559^30
;;^UTILITY(U,$J,358.3,11569,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11569,1,3,0)
;;=3^Transfusion Associated Circulatory Overload
;;^UTILITY(U,$J,358.3,11569,1,4,0)
;;=4^E87.71
;;^UTILITY(U,$J,358.3,11569,2)
;;=^5003024
;;^UTILITY(U,$J,358.3,11570,0)
;;=D63.1^^46^560^1
;;^UTILITY(U,$J,358.3,11570,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11570,1,3,0)
;;=3^Anemia in Chronic Kidney Disease
;;^UTILITY(U,$J,358.3,11570,1,4,0)
;;=4^D63.1
;;^UTILITY(U,$J,358.3,11570,2)
;;=^332908
;;^UTILITY(U,$J,358.3,11571,0)
;;=I12.0^^46^560^7
;;^UTILITY(U,$J,358.3,11571,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11571,1,3,0)
;;=3^HTN w/ CKD w/ Stage 5 CKD/ESRD
;;^UTILITY(U,$J,358.3,11571,1,4,0)
;;=4^I12.0
;;^UTILITY(U,$J,358.3,11571,2)
;;=^5007065
;;^UTILITY(U,$J,358.3,11572,0)
;;=I95.1^^46^560^11
;;^UTILITY(U,$J,358.3,11572,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11572,1,3,0)
;;=3^Hypotension,Orthostatic
;;^UTILITY(U,$J,358.3,11572,1,4,0)
;;=4^I95.1
;;^UTILITY(U,$J,358.3,11572,2)
;;=^60741
;;^UTILITY(U,$J,358.3,11573,0)
;;=I95.89^^46^560^12
;;^UTILITY(U,$J,358.3,11573,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11573,1,3,0)
;;=3^Hypotension,Other
;;^UTILITY(U,$J,358.3,11573,1,4,0)
;;=4^I95.89
;;^UTILITY(U,$J,358.3,11573,2)
;;=^5008079
;;^UTILITY(U,$J,358.3,11574,0)
;;=N17.9^^46^560^13
;;^UTILITY(U,$J,358.3,11574,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11574,1,3,0)
;;=3^Kidney Failure,Acute,Unspec
;;^UTILITY(U,$J,358.3,11574,1,4,0)
;;=4^N17.9
;;^UTILITY(U,$J,358.3,11574,2)
;;=^338532
;;^UTILITY(U,$J,358.3,11575,0)
;;=N18.5^^46^560^3
;;^UTILITY(U,$J,358.3,11575,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11575,1,3,0)
;;=3^Chronic Kidney Disease,Stage 5
;;^UTILITY(U,$J,358.3,11575,1,4,0)
;;=4^N18.5
;;^UTILITY(U,$J,358.3,11575,2)
;;=^5015606
;;^UTILITY(U,$J,358.3,11576,0)
;;=N18.9^^46^560^4
;;^UTILITY(U,$J,358.3,11576,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11576,1,3,0)
;;=3^Chronic Kidney Disease,Unspec
;;^UTILITY(U,$J,358.3,11576,1,4,0)
;;=4^N18.9
;;^UTILITY(U,$J,358.3,11576,2)
;;=^332812
;;^UTILITY(U,$J,358.3,11577,0)
;;=N39.0^^46^560^15
;;^UTILITY(U,$J,358.3,11577,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11577,1,3,0)
;;=3^Urinary Tract Infection,Unspec Site
;;^UTILITY(U,$J,358.3,11577,1,4,0)
;;=4^N39.0
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0PQ 3777 printed Sep 23, 2025@19:29:21 Page 2
IBDEI0PQ ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,11565,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,11565,1,3,0)
+4 ;;=3^Secondary Hyperparathyroidism of Renal Origin
+5 ;;^UTILITY(U,$J,358.3,11565,1,4,0)
+6 ;;=4^N25.81
+7 ;;^UTILITY(U,$J,358.3,11565,2)
+8 ;;=^5015617
+9 ;;^UTILITY(U,$J,358.3,11566,0)
+10 ;;=E22.2^^46^559^28
+11 ;;^UTILITY(U,$J,358.3,11566,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,11566,1,3,0)
+14 ;;=3^SIADH
+15 ;;^UTILITY(U,$J,358.3,11566,1,4,0)
+16 ;;=4^E22.2
+17 ;;^UTILITY(U,$J,358.3,11566,2)
+18 ;;=^5002718
+19 ;;^UTILITY(U,$J,358.3,11567,0)
+20 ;;=E87.79^^46^559^10
+21 ;;^UTILITY(U,$J,358.3,11567,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,11567,1,3,0)
+24 ;;=3^Fluid Overload,Other
+25 ;;^UTILITY(U,$J,358.3,11567,1,4,0)
+26 ;;=4^E87.79
+27 ;;^UTILITY(U,$J,358.3,11567,2)
+28 ;;=^5003025
+29 ;;^UTILITY(U,$J,358.3,11568,0)
+30 ;;=E21.0^^46^559^27
+31 ;;^UTILITY(U,$J,358.3,11568,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,11568,1,3,0)
+34 ;;=3^Primary Hyperparathyroidism
+35 ;;^UTILITY(U,$J,358.3,11568,1,4,0)
+36 ;;=4^E21.0
+37 ;;^UTILITY(U,$J,358.3,11568,2)
+38 ;;=^331439
+39 ;;^UTILITY(U,$J,358.3,11569,0)
+40 ;;=E87.71^^46^559^30
+41 ;;^UTILITY(U,$J,358.3,11569,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,11569,1,3,0)
+44 ;;=3^Transfusion Associated Circulatory Overload
+45 ;;^UTILITY(U,$J,358.3,11569,1,4,0)
+46 ;;=4^E87.71
+47 ;;^UTILITY(U,$J,358.3,11569,2)
+48 ;;=^5003024
+49 ;;^UTILITY(U,$J,358.3,11570,0)
+50 ;;=D63.1^^46^560^1
+51 ;;^UTILITY(U,$J,358.3,11570,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,11570,1,3,0)
+54 ;;=3^Anemia in Chronic Kidney Disease
+55 ;;^UTILITY(U,$J,358.3,11570,1,4,0)
+56 ;;=4^D63.1
+57 ;;^UTILITY(U,$J,358.3,11570,2)
+58 ;;=^332908
+59 ;;^UTILITY(U,$J,358.3,11571,0)
+60 ;;=I12.0^^46^560^7
+61 ;;^UTILITY(U,$J,358.3,11571,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,11571,1,3,0)
+64 ;;=3^HTN w/ CKD w/ Stage 5 CKD/ESRD
+65 ;;^UTILITY(U,$J,358.3,11571,1,4,0)
+66 ;;=4^I12.0
+67 ;;^UTILITY(U,$J,358.3,11571,2)
+68 ;;=^5007065
+69 ;;^UTILITY(U,$J,358.3,11572,0)
+70 ;;=I95.1^^46^560^11
+71 ;;^UTILITY(U,$J,358.3,11572,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,11572,1,3,0)
+74 ;;=3^Hypotension,Orthostatic
+75 ;;^UTILITY(U,$J,358.3,11572,1,4,0)
+76 ;;=4^I95.1
+77 ;;^UTILITY(U,$J,358.3,11572,2)
+78 ;;=^60741
+79 ;;^UTILITY(U,$J,358.3,11573,0)
+80 ;;=I95.89^^46^560^12
+81 ;;^UTILITY(U,$J,358.3,11573,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,11573,1,3,0)
+84 ;;=3^Hypotension,Other
+85 ;;^UTILITY(U,$J,358.3,11573,1,4,0)
+86 ;;=4^I95.89
+87 ;;^UTILITY(U,$J,358.3,11573,2)
+88 ;;=^5008079
+89 ;;^UTILITY(U,$J,358.3,11574,0)
+90 ;;=N17.9^^46^560^13
+91 ;;^UTILITY(U,$J,358.3,11574,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,11574,1,3,0)
+94 ;;=3^Kidney Failure,Acute,Unspec
+95 ;;^UTILITY(U,$J,358.3,11574,1,4,0)
+96 ;;=4^N17.9
+97 ;;^UTILITY(U,$J,358.3,11574,2)
+98 ;;=^338532
+99 ;;^UTILITY(U,$J,358.3,11575,0)
+100 ;;=N18.5^^46^560^3
+101 ;;^UTILITY(U,$J,358.3,11575,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,11575,1,3,0)
+104 ;;=3^Chronic Kidney Disease,Stage 5
+105 ;;^UTILITY(U,$J,358.3,11575,1,4,0)
+106 ;;=4^N18.5
+107 ;;^UTILITY(U,$J,358.3,11575,2)
+108 ;;=^5015606
+109 ;;^UTILITY(U,$J,358.3,11576,0)
+110 ;;=N18.9^^46^560^4
+111 ;;^UTILITY(U,$J,358.3,11576,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,11576,1,3,0)
+114 ;;=3^Chronic Kidney Disease,Unspec
+115 ;;^UTILITY(U,$J,358.3,11576,1,4,0)
+116 ;;=4^N18.9
+117 ;;^UTILITY(U,$J,358.3,11576,2)
+118 ;;=^332812
+119 ;;^UTILITY(U,$J,358.3,11577,0)
+120 ;;=N39.0^^46^560^15
+121 ;;^UTILITY(U,$J,358.3,11577,1,0)
+122 ;;=^358.31IA^4^2
+123 ;;^UTILITY(U,$J,358.3,11577,1,3,0)
+124 ;;=3^Urinary Tract Infection,Unspec Site
+125 ;;^UTILITY(U,$J,358.3,11577,1,4,0)
+126 ;;=4^N39.0
